Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review

[1]  O. González-Valle,et al.  16415 Combination therapy of apremilast and biologic agent as a step-up strategy option of psoriasis and psoriatic arthritis , 2020 .

[2]  M. González-Gay,et al.  Treating multidrug‐resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID‐19 pandemic , 2020, Dermatologic therapy.

[3]  H. Ke,et al.  Advances in the development of phosphodiesterase-4 inhibitors. , 2020, Journal of medicinal chemistry.

[4]  C. Griffiths,et al.  Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) , 2020, The British journal of dermatology.

[5]  Y. Teraki,et al.  Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue , 2019, The Journal of dermatology.

[6]  A. Patrizi,et al.  Combination therapy of apremilast and secukinumab in patients with moderate‐to‐severe, recalcitrant plaque psoriasis , 2019, Clinical and experimental dermatology.

[7]  Abhishek De,et al.  Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic , 2019, Indian journal of dermatology.

[8]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. , 2019, Journal of the American Academy of Dermatology.

[9]  M. Nisar.  Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach , 2018, European journal of rheumatology.

[10]  A. Quismorio,et al.  Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. , 2019, Current rheumatology reviews.

[11]  Heng Li,et al.  Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases , 2018, Front. Pharmacol..

[12]  M. Gooderham,et al.  Eight-Patient Case Series of Palmoplantar Pustulosis Treated Successfully With Apremilast , 2018, Journal of Psoriasis and Psoriatic Arthritis.

[13]  A. Gottlieb,et al.  Apremilast in Combination With an Interleukin 17A Inhibitor in the Treatment of Recalcitrant Palmoplantar Psoriasis , 2018, Journal of Psoriasis and Psoriatic Arthritis.

[14]  M. Komine,et al.  Real‐world use of apremilast for patients with psoriasis in Japan , 2018, The Journal of dermatology.

[15]  L. Bianchi,et al.  Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy , 2018, Molecular Diagnosis & Therapy.

[16]  J. Linder,et al.  Comparative effectiveness of targeted immunomodulators for the treatment of moderate‐to‐severe plaque psoriasis: A systematic review and network meta‐analysis , 2018, Journal of the American Academy of Dermatology.

[17]  N. Shear,et al.  Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study , 2018, Journal of the American Academy of Dermatology.

[18]  H. Marzo-Ortega,et al.  Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. , 2018, Rheumatology.

[19]  L. Skov,et al.  Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis , 2018, The British journal of dermatology.

[20]  N. Shear,et al.  A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study , 2017, Journal of the American Academy of Dermatology.

[21]  K. Peris,et al.  Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) , 2017, Journal of the American Academy of Dermatology.

[22]  J. Yeung,et al.  Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report , 2017, Journal of cutaneous medicine and surgery.

[23]  M. Lebwohl,et al.  Secukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis , 2017 .

[24]  J. Gooderham.  Treatment of Palmoplantar Pustulosis with the Combination of Ustekinumab and Apremilast: A Case Report , 2016 .

[25]  Lei Wu,et al.  Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. , 2016, Cellular signalling.

[26]  A. Gottlieb,et al.  Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis. , 2016, Journal of drugs in dermatology : JDD.

[27]  N. Shear,et al.  Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis , 2016, Journal of cutaneous medicine and surgery.

[28]  J. Koo,et al.  Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. , 2015, Dermatology online journal.

[29]  A. Armstrong,et al.  Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. , 2015, JAMA dermatology.

[30]  R. Dellavalle,et al.  Systematic reviews: grading recommendations and evidence quality. , 2008, Archives of dermatology.